Osteoarticular Expression of Musashi-1 in an Experimental Model of Arthritis

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  O'Valle, Francisco ^a   Peregrina, Magdalena ^b   Crespo Lora, Vicente ^a   Galindo Moreno, Pablo ^a   Roman, Maria ^c   Padial Molina, Miguel ^a   Mesa, Francisco ^a   Aneiros Fernandez, Jose ^a   Aguilar, David ^a   Gonzalez Rey, Elena ^d   Delgado, Mario ^d   Hernandez Cortes, Pedro ^e  

^a UNIVERSITY OF GRANADA   (Spain)

^b Spanish Institute of Social Security ^*  (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^e HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL MARKER; CYTOKINE; ETANERCEPT; MUSASHI 1 PROTEIN; UNCLASSIFIED DRUG; MSI1 PROTEIN, HUMAN; NERVE PROTEIN; RNA BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; JOINT INJURY; LIMB INJURY; MALE; MOUSE; NONHUMAN; OSTEOARTHROPATHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TISSUE LEVEL; TISSUE REPAIR; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; DISEASE MODEL; EXPERIMENTAL ARTHRITIS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RHEUMATOID ARTHRITIS; STEM CELL;

MURINAE; MUS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; HUMANS; MICE; NERVE TISSUE PROTEINS; RNA-BINDING PROTEINS; STEM CELLS;

EID: 84929643535     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/681456     Document Type: Article

References (45)

1. D. D. Anthony and T. M. Haqqi, "Collagen-induced arthritis in mice: an animal model to study the pathogenesis of rheumatoid arthritis," Clinical and Experimental Rheumatology, vol. 17, no. 2, pp. 240-244, 1999.
2. M. Feldmann, F. M. Brennan, and R. N. Maini, "Role of cytokines in rheumatoid arthritis," Annual Review of Immunology, vol. 14, pp. 397-440, 1996.
3. D. D. Brand, A. H. Kang, and E. F. Rosloniec, "Immunopathogenesis of collagen arthritis," Springer Seminars in Immunopathology, vol. 25, no. 1, pp. 3-18, 2003.
4. E. Gonzalez-Rey, A. Chorny, F. O'Valle, and M. Delgado, "Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells," The American Journal of Pathology, vol. 170, no. 1, pp. 263-271, 2007.
5. M. Feldmann and R. N. Maini, "Anti-TNFalpha therapy of rheumatoid arthritis: what have we learned?" Annual Review of Immunology, vol. 19, pp. 163-196, 2001.
6. J. C. Beckham, D. S. Caldwell, B. L. Peterson et al., "Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-α, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures," Journal of Clinical Immunology, vol. 12, no. 5, pp. 353-361, 1992.
7. F. M. Brennan, D. Chantry, A. Jackson, R. Maini, and M. Feldmann, "Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis," The Lancet, vol. 2, no. 8657, pp. 244-247, 1989.
8. X. Sáez-Llorens, H. S. Jafari, K. D. Olsen, H. Nariuchi, E. J. Hansen, and G. H. McCracken Jr., "Induction of suppurative arthritis in rabbits by Haemophilus endotoxin, tumor necrosis factor-α, and interleukin-1β," Journal of Infectious Diseases, vol. 163, no. 6, pp. 1267-1272, 1991.
9. D. Tracey, L. Klareskog, E. H. Sasso, J. G. Salfeld, and P. P. Tak, "Tumor necrosis factor antagonist mechanisms of action: a comprehensive review," Pharmacology & Therapeutics, vol. 117, no. 2, pp. 244-279, 2008.
10. S. Dhillon, K. A. Lyseng-Williamson, and L. J. Scott, "Etanercept: a review of its use in the management of rheumatoid arthritis," Drugs, vol. 67, no. 8, pp. 1211-1241, 2007.
11. B. Haraoui and V. Bykerk, "Etanercept in the treatment of rheumatoid arthritis," Therapeutics and Clinical Risk Management, vol. 3, no. 1, pp. 99-105, 2007.
12. G. J. Thorbecke, R. Shah, C. H. Leu, A. P. Kuruvilla, A. M. Hardison, and M. A. Palladino, "Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 16, pp. 7375-7379, 1992.
13. R. O. Williams, M. Feldmann, and R. N. Maini, "Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis," Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 20, pp. 9784-9788, 1992.
14. P. F. Piguet, G. E. Grau, C. Vesin, H. Loetscher, R. Gentz, and W. Lesslauer, "Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor," Immunology, vol. 77, no. 4, pp. 510-514, 1992.
15. P. H. Wooley, J. Dutcher, M. B. Widmer, and S. Gillis, "Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice,"Journal of Immunology, vol. 151, no. 11, pp. 6602-6607, 1993.
16. R. O. Williams, J. Ghrayeb, M. Feldmann, and R. N. Maini, "Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4,"Immunology, vol. 84, no. 3, pp. 433-439, 1995.
17. Q. T. Wang, Y. J. Wu, B. Huang et al., "Etanercept attenuates collagen-induced arthritis by modulating the association between BAFFR expression and the production of splenic memory B cells," Pharmacological Research, vol. 68, no. 1, pp. 38-45, 2013.
18. T. Nagata, R. Kanno, Y. Kurihara et al., "Structure, backbone dynamics and interactions with RNA of the C-terminal RNA-binding domain of a mouse neural RNA-binding protein, Musashi1," The Journal of Molecular Biology, vol. 287, no. 2, pp. 315-330, 1999.
19. H. Okano, H. Kawahara, M. Toriya, K. Nakao, S. Shibata, and T. Imai, "Function of RNA-binding protein Musashi-1 in stem cells," Experimental Cell Research, vol. 306, no. 2, pp. 349-356, 2005.
20. H. Okano, T. Imai, and M. Okabe, "Musashi: a translational regulator of cell fate," Journal of Cell Science, vol. 115, no. 7, pp. 1355-1359, 2002.
21. Y. Kaneko, S. Sakakibara, T. Imai et al., "Musashi1: an evolutionally conserved marker for CNS progenitor cells including neural stem cells," Developmental Neuroscience, vol. 22,no. 1-2, pp. 139-153, 2000.
22. S. M. Sureban, R. May, R. J. George et al., "Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo,"Gastroenterology, vol. 134, no. 5, pp. 1448-1458, 2008.
23. T. Fukui, H. Takeda, H.-J. Shu et al., "Investigation of Musashi-1 expressing cells in themurine model of dextran sodium sulfate-induced colitis," Digestive Diseases and Sciences, vol. 51, no. 7, pp. 1260-1268, 2006.
24. X. Liu, W. T. Yang, and P. S. Zheng, "Msi1 promotes tumor growth and cell proliferation by targeting cell cycle checkpoint proteins p21, p27 and p53 in cervical carcinomas," Oncotarget, vol. 5, no. 21, pp. 10870-10885, 2014.
25. M. Delgado, C. Abad, C. Martinez, J. Leceta, and R. P. Gomariz, "Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease," Nature Medicine, vol. 7, no. 5, pp. 563-568, 2001.
26. K. Kannan, R. A. Ortmann, and D. Kimpel, "Animal models of rheumatoid arthritis and their relevance to human disease,"Pathophysiology, vol. 12, no. 3, pp. 167-181, 2005.
27. Y. G. Cho, M. L. Cho, S. Y. Min, and H. Y. Kim, "Type II collagen autoimmunity in amousemodel of human rheumatoid arthritis," Autoimmunity Reviews, vol. 7, no. 1, pp. 65-70, 2007.
28. R. Holmdahl, L. Jansson, E. Larsson, K. Rubin, and L. Klareskog, "Homologous type II collagen induces chronic and progressive arthritis in mice," Arthritis&Rheumatism, vol. 29,no. 1, pp. 106-113, 1986.
29. A. M. Malfait, R. O. Williams, A. S. Malik, R. N. Maimi, and M. Feldman, "Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies," Arthritis &Rheumatism, vol. 44, no. 5, pp. 1215-1224, 2001.
30. J. M. Stuart, M. A. Cremer, A. S. Townes, and A. H. Kang, "Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis," Journal of Experimental Medicine, vol. 155, no. 1, pp. 1-16, 1982.
31. R. Holmdahl, M. E. Andersson, T. J. Goldschmidt et al., "Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity,"APMIS, vol. 97, no. 7, pp. 575-584, 1989.
32. R. O. Williams, "Rodent models of arthritis: relevance for human disease," Clinical and Experimental Immunology, vol. 114, no. 3, pp. 330-332, 1998.
33. S. Rose, M. Eren, S. Murphy et al., "A novel mouse model that develops spontaneous arthritis and is predisposed towards atherosclerosis," Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 89-95, 2013.
34. A. V. Misharin, G. K. Haines III, S. Rose, A. K. Gierut, R. S. Hotchkiss, and H. Perlman, "Development of a new humanized mouse model to study acute inflammatory arthritis," Journal of Translational Medicine, vol. 10, no. 1, article no. 190, 2012.
35. A. H. Tremouler and S. Albani, "Novel therapies for rheumatoid arthritis," Expert Opinion on Investigational Drugs, vol. 15, no. 11, pp. 1427-1441, 2006.
36. J. J. Goronzy and C. M. Wey and, "Rheumatoid arthritis," Immunological Reviews, vol. 204, no. 1, pp. 55-73, 2005.
37. E. Gonzalez-Rey, R. Martínez-Romero, F. O'Valle et al., "Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response," PLoS ONE, vol. 2, no. 10, Article IDe1071, 2007.
38. R. O. Williams, "Collagen-induced arthritis in mice: a major role for tumor necrosis factor-α," Methods in Molecular Biology, vol. 361, pp. 265-284, 2007.
39. J. Zwerina, S. Hayer, M. Tohidast-Akrad et al., "Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction," Arthritis and Rheumatism, vol. 50, no. 1, pp. 277-290, 2004.
40. K. E. Donahue, G. Gartlehner, D. E. Jonas et al., "Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis," Annals of Internal Medicine, vol. 148, no. 2, pp. 124-134, 2008.
41. L. W. Moreland, S. W. Baumgartner, M. H. Schiff et al., "Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein," The New England Journal of Medicine, vol. 337, no. 3, pp. 141-147, 1997.
42. L. W. Moreland, M. H. Schiff, S. W. Baumgartner et al., "Phase III trial of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR: Fc, ENBREL),"Journal of Investigative Medicine, vol. 46, p. 228A, 1998, Abstract.
43. É. Toussirot and D. Wendling, "The use of TNF-α blocking agents in rheumatoid arthritis: an overview," Expert Opinion on Pharmacotherapy, vol. 5, no. 3, pp. 581-594, 2004.
44. J. M. Sutherland, E. A. McLaughlin, G. R. Hime, and N. A. Siddall, "The Musashi family of RNA binding proteins: master regulators of multiple stem cell populations," Advances in Experimental Medicine and Biology, vol. 786, pp. 233-245, 2013.
45. T. Takahashi, H. Suzuki, T. Imai et al., "Musashi-1 post-transcriptionally enhances phosphotyrosine-binding domain-containing m-Numb protein expression in regenerating gastric mucosa," PLoS ONE, vol. 8, no. 1, Article ID e53540, 2013.